Analgesic Efficacy of Surgeon-administered Transversus Abdominis Plane Blocks for Caesarean Section.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06324942

Enrollment

Registered

2024-03-22

Start date

2025-02-19

Completion date

2026-12-01

Last updated

2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Section Complications, Pain, Postoperative

Brief summary

The purpose of this research study is to evaluate whether or not adding a Transversus Abdominis Plane Block (TAP block) improves pain control for patients having a cesarean section. A TAP block is a type of nerve block where at the end of the surgery an injection of a long acting local anesthetic is made into the abdominal wall. In studies in patient's having other abdominal surgeries this has reduced the amount of narcotics patients need for pain control. This may also led to patients being more active after surgery and maybe spending less time in hospital.

Detailed description

Randomized clinical trial of Transversus Abdominis Plane Block (TAP block) at Cesarean Section.

Interventions

OTHERSurgeon-administered Transversus Abdominis Plane Block 0.25% bupivicaine 0.25 mL/kg

Surgeon-administered Transversus Abdominis Plane Block

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* ASA status II to III * All patients undergoing elective CS under regional anesthesia at any gestational age.

Exclusion criteria

* \- Known drug allergy to local anesthetics * Planned general anesthetic * NSAID use contraindicated post partum * Chronic pain disorder or chronic narcotic use/dependence * Planned vertical abdominal incision * Planned Cesarean Hysterectomy. * Placenta Previa or suspected Placenta Accreta

Design outcomes

Primary

Measure	Time frame	Description
Post operative Pain	12 hours post op	VAS scale 0-no pain to 10-worst pain

Secondary

Measure	Time frame	Description
Time to first request for rescue analgesia in hours	48 hours post op	Time from completion of surgery to first request for rescue analgesia in hours
Post operative Opioid use	up to 48 hours post op.	Total opioid consumption in the first 24h and 48h mark, postoperatively
Time from surgery to discharge from hospital	Up to discharge from hospital, usually 1-3 days	Time from completion of surgery to discharge

Countries

Canada

Contacts

CONTACTStephen Wood, MD

slwood@ucalgary.ca4039441438

PRINCIPAL_INVESTIGATORStephen Wood, MD

University of Calgary

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 16, 2026